Skip Navigation
Pipeline

Black Diamond’s Unique Approach

Target
Candidate / Indication
Discovery
Optimization
IND-Enabling
Phase 1
Phase 2
Phase 3
EGFR

BDTX-1535

GBM, NSCLC
  • Discovery CompletedDiscovery % Completed
  • Optimization CompletedOptimization % Completed
  • IND-Enabling CompletedIND-Enabling % Completed
  • Phase 1 10% Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Phase 1

BDTX-1535 is designed to be a potent, selective, brain penetrant and irreversible MasterKey inhibitor of EGFR mutations that expressed in glioblastoma multiforme (GBM) and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer (NSCLC).

EGFR
HER2

BDTX-189

NSCLC, Breast, Others
  • Discovery CompletedDiscovery % Completed
  • Optimization CompletedOptimization % Completed
  • IND-Enabling CompletedIND-Enabling % Completed
  • Phase 1 50% Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Phase 1

BDTX-189 is designed to be an orally available, irreversible small molecule inhibitor that targets undrugged oncogenic driver mutations of the EGFR and HER2 kinases.

BRAF

Undisclosed

Multiple solid tumors
  • Discovery CompletedDiscovery % Completed
  • Optimization 30% Completed
  • IND-Enabling % Completed
  • Phase 1 % Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Optimization

BDTX BRAF compounds are designed to target all the MasterKey mutations comprised of Class I, Class II, and Class III mutations while avoiding paradoxical activation by inhibiting dimerized RAF kinase and to be brain penetrant to treat CNS diseases.

FGFR

Undisclosed

Multiple solid tumors
  • Discovery CompletedDiscovery % Completed
  • Optimization 30% Completed
  • IND-Enabling % Completed
  • Phase 1 % Completed
  • Phase 2 % Completed
  • Phase 3 % Completed
Optimization

BDTX FGFR program compounds are MasterKey inhibitors of allosteric FGFR2/3 mutations with selectivity versus FGFR1 and activity against clinically relevant resistance mutations.

Utilizing our proprietary MAP platform, we are developing a pipeline of orally available, potent, and selective drug candidates that target a range of driver mutations in cancer.

Our first two disclosed programs are targeting groups of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor2 (HER2) allosteric mutants. We are also progressing our early stage pipeline programs targeting groups of canonical and non-canonical mutations in kinases relevant to cancer and/or rare genetic diseases. These programs, which we have developed using our MAP platform, are currently progressing through lead optimization.